Drug Combination Details
| General Information of the Combination (ID: C57697) | |||||
|---|---|---|---|---|---|
| Name | Honokiol NP Info | + | Osimertinib Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Lung cancer
[ICD-11: 2C25]
|
Investigative | [1] | ||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Reversing Drug Resistance by This Combination | ||||||
| Reversing Drug Resistance | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [1] | |||||
| Molecule(s)
Regulation |
Down-regulation | Expression | MCL1 | Molecule Info |
Pathway MAP
|
|
| In-vitro Model | PC-9 | CVCL_B260 | Lung adenocarcinoma | Homo sapiens | ||
| HCC827 | CVCL_2063 | Lung adenocarcinoma | Homo sapiens | |||
| Experimental
Result(s) |
Overcoming acquired resistance of EGFR-mutant NSCLC cells to the third generation EGFR inhibitor, osimertinib, with the natural product honokiol. | |||||
